ArticleEuropean journal of drug metabolism and pharmacokinetics2026
Beyond Algorithms: Machine Learning and Clinical Determinants of Voriconazole Plasma Levels in Therapeutic Drug Monitoring.
Article in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveVoriconazole is a broad-spectrum antifungal agent whose efficacy and toxicity are closely related to plasma concentrations, which are highly variable between individuals. Therapeutic drug monitoring (TDM) helps optimize its use but is not always available. In this context, machine learning may help predict subtherapeutic or supratherapeutic levels before TDM results are obtained.
methodsThis was a single-center retrospective study conducted between May 2021 and June 2024 in a tertiary hospital in northern Spain. Adult patients treated with voriconazole for at least 3 days and with a steady-state plasma level measurement were included. Clinical, laboratory, and treatment-related variables were collected. Supervised machine learning models (random forest, support vector machines (SVM), XGBoost, etc.) were trained to classify plasma levels as subtherapeutic, therapeutic, or supratherapeutic.
resultsA total of 147 patients were included (65% male; median age 65 years). Therapeutic concentrations were found in 71% of patients, supratherapeutic in 15%, and subtherapeutic in 14%. Significant differences were observed on the basis of route of administration, dosage form, age, liver function, and certain comorbidities. Aspartate aminotransferase (AST), glomerular filtration rate, and administration route were the most relevant predictors in the models. Random forest achieved the best performance (area under the curve (AUC) 0.675), though still below the threshold for clinical applicability.
conclusionsAlthough machine learning models identified relevant predictors of voriconazole exposure, their predictive accuracy was limited and insufficient to replace therapeutic drug monitoring. TDM remains essential for individualized and safe dosing. Integrating pharmacogenetic data and hybrid models combining TDM and computational tools may improve predictive performance and clinical applicability.
Indexed as
Identifiers
41288921What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.